Fibroblast growth factor receptor 2 (FGFR2) is one of four FGFR family members that encode transmembrane receptor tyrosine kinases. FGFR2b is the IIIb splice isoform of FGFR2.1

Expression of FGFRs and their corresponding ligands, fibroblast growth factors, contributes to tumor progression in human malignancies by enhancing angiogenesis and proliferation.2,3 Patients whose tumors have amplification of the FGFR2 gene tend to have a poor prognosis.4-7

In tumors with FGFR2 amplification, it is the FGFR2b splice variant that is almost invariably expressed on the cell surface.8-10

FGFR2b overexpression is observed in 3%–61% of gastric and gastroesophageal junction cancers depending on tumor stage, assay, and study cutoff,1,4,11-13 and has been reported in various other cancers as well,14-19 suggesting that targeting FGFR2b may be an important therapeutic strategy.

Learn more about modalities targeting FGFR2b:
monoclonal antibodies.

Download an educational resource for additional information on FGFR2b, a therapeutic target in gastric cancer.
Download an educational presentation with information on FGFR2b, a therapeutic target in gastric cancer.

Search our clinical trials.

Visit our resources section for additional information on potential oncogenic targets.


1. Han N, Kim MA, Lee HS, Kim WH. Pathobiology. 2015;82(6):269-279. 2. Presta M, Dell’Era P, Mitola S, et al. Cytokine Growth Factor Rev. 2005;16(2):159-178. 3. Grose R, Dickson C. Cytokine Growth Factor Rev. 2005;16(2):179-186. 4. Ahn S, Lee J, Hong M, et al. Mod Pathol. 2016;29(9):1095-1103. 5. Su X, Zhan P, Gavine P, et al. Br J Cancer. 2014;110(4):967-975. 6. Seo S, Park S, Ryu M-H, et al. Oncotarget. 2017;8(20):33844-33854. 7. Jung E-J, Jung E-J, Min S, Kim MA, Kim WH. Hum Pathol. 2012;43(10):1559-1566. 8. Turner N, Grose R. Nat Rev Cancer. 2010;10(2):116-129. 9. Ornitz DM, Xu J, Colvin JS, et al. J Biol Chem. 1996;271(25):15292-15297. 10. Bai A, Meetze K, Vo NY, et al. Cancer Res. 2010;70(19):7630-7639. 11.  Nagatsuma AK, Aizawa M, Kuwata T, et al. Gastric Cancer. 2015;18(2):227-238. 12. Tokunaga R, Imamura Y, Nakamura K, et al. Oncotarget. 2016;7(15):19748-19761. 13. Wainberg ZA, Enzinger P, Kang YK, et al. Presented at: ASCO Gastrointestinal Cancer Symposium; January 15-17, 2021; Online Virtual Scientific Program. Abstract LBA160. 14. Yoshino M, Ishiwata T, Watanabe M, et al. Int J Oncol. 2007;31(4):721-728. 15. Ishiwata T, Friess H, Büchler MW, Lopez ME, Korc M. Am J Pathol. 1998;153(1):213-222. 16. Kurban G, Ishiwata T, Kudo M, et al. Oncol Rep. 2004;11(5):987-991. 17. Yamayoshi T, Nagayasu T, Matsumoto K, et al. J Pathol. 2004;204(1):110-118. 18. Cho K, Ishiwata T, Uchida E, et al. Am J Pathol. 2007;170(6):1964-1974. 19. Watanabe M, Ishiwata T, Nishigai K, Moriyama Y, Asano G. Pathol Int. 2000;50(5):363-372.